<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04482049</url>
  </required_header>
  <id_info>
    <org_study_id>REN001-903</org_study_id>
    <nct_id>NCT04482049</nct_id>
  </id_info>
  <brief_title>A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders</brief_title>
  <acronym>FORWARD</acronym>
  <official_title>A Prospective, Multicenter, Non-interventional Study to Investigate the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders (FAOD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reneo Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reneo Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to collect information on disease characteristics from adult&#xD;
      patients diagnosed with fatty acid oxidation disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study there will be no drug intervention. The study will include a Baseline visit and&#xD;
      a follow up visit scheduled at Month 4. At these visits medical history, safety assessments,&#xD;
      concomitant medications, exercise tests and quality of life questionnaire data will be&#xD;
      collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate change in function as measured by 12 minute walk test in adult subjects with long-chain fatty acid oxidation disorders</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from baseline 12mwt</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate change in symptoms related to FAOD using a newly developed muscle symptom questionnaire specifically designed for adult patients with long-chain FAOD</measure>
    <time_frame>Week 16</time_frame>
    <description>Change from baseline in FAOD-Muscle Symptom Inventory</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Fatty Acid Oxidation Disorder</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from centres experienced in the identification and subsequent&#xD;
        management of patients LC-FAOD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of one of the following genetically confirmed:&#xD;
&#xD;
               1. Carnitine palmitoyltransferase 2 deficiency&#xD;
&#xD;
               2. Very long-chain Acyl-CoA dehydrogenase deficiency&#xD;
&#xD;
               3. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency&#xD;
&#xD;
               4. Trifunctional protein deficiency&#xD;
&#xD;
          2. A stable treatment regimen for at least 30 days&#xD;
&#xD;
          3. Ambulatory and able to perform the study exercise test, using walking aids if&#xD;
             necessary&#xD;
&#xD;
          4. Willing and able to personally sign and date an informed consent document indicating&#xD;
             that the subject has been informed of all pertinent aspects of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable or poorly controlled disease as determined by one or more of the following:&#xD;
&#xD;
               1. Presence of symptoms of acute rhabdomyolysis with clinically significant&#xD;
                  elevations in serum CK&#xD;
&#xD;
               2. Evidence of acute crisis from their underlying disease&#xD;
&#xD;
          2. Currently taking a PPAR agonist&#xD;
&#xD;
          3. Have motor abnormalities other than those related to the fatty acid oxidation disorder&#xD;
             that could interfere with the study procedures, as determine by the investigator&#xD;
&#xD;
          4. Evidence of significant concomitant medical or psychiatric disease that in the opinion&#xD;
             of the Investigator may interfere with the conduct or safety of this study&#xD;
&#xD;
          5. Pregnant or nursing females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie Gillingham, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Molecular and Medical Genetics, Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Purkins, PhD</last_name>
    <phone>01304 809360</phone>
    <email>clintrialinfo@reneopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbuilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze, Klinika pediatrie a dedicnych poruch metabolizmu</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Klinik for nerve- og muskelsygdomme</name>
      <address>
        <city>København</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>Clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flór Ferenc Kórház</name>
      <address>
        <city>Kistarcsa</city>
        <zip>H-2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico &quot;G. Martino&quot; di Messina</name>
      <address>
        <city>Messina</city>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Kliniczny Chorób Metabolicznych i Diabetologii Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>30-688</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>Clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Matki i Dziecka Klinika Wrodzonych Wad Metabolizmu i Pediatrii</name>
      <address>
        <city>Warszawa</city>
        <zip>01-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidad de Diagnóstico y Tratamiento de Enfermedades Metabólicas Complejo Hospitalario Universitario de Santiago Travesía de Choupana s/n</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. George's Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW170QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contract</last_name>
      <email>clintrialinfo@reneopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

